Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection.
Identifieur interne : 002631 ( PubMed/Curation ); précédent : 002630; suivant : 002632Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection.
Auteurs : Yao-Hsu Yang [Taïwan] ; Yu-Hui Huang ; Ya-Hui Chuang ; Chung-Min Peng ; Li-Chieh Wang ; Yu-Tsan Lin ; Bor-Luen ChiangSource :
- Journal of medical virology [ 0146-6615 ] ; 2005.
Descripteurs français
- KwdFr :
- Adulte, Anticorps antiviraux (sang), Autoanticorps (pharmacologie), Cellules endothéliales (), Cellules épithéliales (), Humains, Immunoglobuline A (sang), Immunoglobuline G (sang), Immunoglobuline M (sang), Lignée cellulaire, Protéines nucléocapside (immunologie), Syndrome respiratoire aigu sévère (immunologie), Test ELISA, Virus du SRAS (immunologie).
- MESH :
- immunologie : Protéines nucléocapside, Syndrome respiratoire aigu sévère, Virus du SRAS.
- pharmacologie : Autoanticorps.
- sang : Anticorps antiviraux, Immunoglobuline A, Immunoglobuline G, Immunoglobuline M.
- Adulte, Cellules endothéliales, Cellules épithéliales, Humains, Lignée cellulaire, Test ELISA.
English descriptors
- KwdEn :
- Adult, Antibodies, Viral (blood), Autoantibodies (pharmacology), Cell Line, Endothelial Cells (drug effects), Enzyme-Linked Immunosorbent Assay, Epithelial Cells (drug effects), Humans, Immunoglobulin A (blood), Immunoglobulin G (blood), Immunoglobulin M (blood), Nucleocapsid Proteins (immunology), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology).
- MESH :
- chemical , blood : Antibodies, Viral, Immunoglobulin A, Immunoglobulin G, Immunoglobulin M.
- chemical , immunology : Nucleocapsid Proteins.
- chemical , pharmacology : Autoantibodies.
- drug effects : Endothelial Cells, Epithelial Cells.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- Adult, Cell Line, Enzyme-Linked Immunosorbent Assay, Humans.
Abstract
The severe acute respiratory syndrome (SARS) is caused by infection with the SARS-associated coronavirus (SARS-CoV) and characterized by severe pulmonary inflammation and fibrosis. In this study, the development of autoantibodies against human epithelial cells and endothelial cells in patients with SARS at different time periods (the first week: phase I, 1 month after the disease onset: phase II/phase III) were investigated. Antibodies in sera of patients and healthy controls against: (1) A549 human pulmonary epithelial cell-line, (2) human umbilical venous endothelial cells (HUVEC), (3) primary human pulmonary endothelial cells (HPEC) were detected by cell-based ELISA and indirect immunofluorescence staining. The results revealed that serum levels of IgG anti-A549 cells antibodies, IgG anti-HUVEC antibodies, and IgM anti-HPEC antibodies were significantly higher in SARS patients at phase II/phase III than those in healthy controls. Sera from SARS patients at phase II/phase III could mediate complement dependent cytotoxicity against some A549 cells and HPEC. It is concluded that some autoantibodies against human epithelial cells and endothelial cells would be developed after SARS-CoV infection and this phenomenon may indicate post-infectious cellular injury and also induce SARS-induced immunopathology.
DOI: 10.1002/jmv.20407
PubMed: 16032747
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002631
Links to Exploration step
pubmed:16032747Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection.</title><author><name sortKey="Yang, Yao Hsu" sort="Yang, Yao Hsu" uniqKey="Yang Y" first="Yao-Hsu" last="Yang">Yao-Hsu Yang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei</wicri:regionArea></affiliation></author><author><name sortKey="Huang, Yu Hui" sort="Huang, Yu Hui" uniqKey="Huang Y" first="Yu-Hui" last="Huang">Yu-Hui Huang</name></author><author><name sortKey="Chuang, Ya Hui" sort="Chuang, Ya Hui" uniqKey="Chuang Y" first="Ya-Hui" last="Chuang">Ya-Hui Chuang</name></author><author><name sortKey="Peng, Chung Min" sort="Peng, Chung Min" uniqKey="Peng C" first="Chung-Min" last="Peng">Chung-Min Peng</name></author><author><name sortKey="Wang, Li Chieh" sort="Wang, Li Chieh" uniqKey="Wang L" first="Li-Chieh" last="Wang">Li-Chieh Wang</name></author><author><name sortKey="Lin, Yu Tsan" sort="Lin, Yu Tsan" uniqKey="Lin Y" first="Yu-Tsan" last="Lin">Yu-Tsan Lin</name></author><author><name sortKey="Chiang, Bor Luen" sort="Chiang, Bor Luen" uniqKey="Chiang B" first="Bor-Luen" last="Chiang">Bor-Luen Chiang</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16032747</idno><idno type="pmid">16032747</idno><idno type="doi">10.1002/jmv.20407</idno><idno type="wicri:Area/PubMed/Corpus">002631</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002631</idno><idno type="wicri:Area/PubMed/Curation">002631</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002631</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection.</title><author><name sortKey="Yang, Yao Hsu" sort="Yang, Yao Hsu" uniqKey="Yang Y" first="Yao-Hsu" last="Yang">Yao-Hsu Yang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei</wicri:regionArea></affiliation></author><author><name sortKey="Huang, Yu Hui" sort="Huang, Yu Hui" uniqKey="Huang Y" first="Yu-Hui" last="Huang">Yu-Hui Huang</name></author><author><name sortKey="Chuang, Ya Hui" sort="Chuang, Ya Hui" uniqKey="Chuang Y" first="Ya-Hui" last="Chuang">Ya-Hui Chuang</name></author><author><name sortKey="Peng, Chung Min" sort="Peng, Chung Min" uniqKey="Peng C" first="Chung-Min" last="Peng">Chung-Min Peng</name></author><author><name sortKey="Wang, Li Chieh" sort="Wang, Li Chieh" uniqKey="Wang L" first="Li-Chieh" last="Wang">Li-Chieh Wang</name></author><author><name sortKey="Lin, Yu Tsan" sort="Lin, Yu Tsan" uniqKey="Lin Y" first="Yu-Tsan" last="Lin">Yu-Tsan Lin</name></author><author><name sortKey="Chiang, Bor Luen" sort="Chiang, Bor Luen" uniqKey="Chiang B" first="Bor-Luen" last="Chiang">Bor-Luen Chiang</name></author></analytic><series><title level="j">Journal of medical virology</title><idno type="ISSN">0146-6615</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antibodies, Viral (blood)</term><term>Autoantibodies (pharmacology)</term><term>Cell Line</term><term>Endothelial Cells (drug effects)</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Epithelial Cells (drug effects)</term><term>Humans</term><term>Immunoglobulin A (blood)</term><term>Immunoglobulin G (blood)</term><term>Immunoglobulin M (blood)</term><term>Nucleocapsid Proteins (immunology)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Anticorps antiviraux (sang)</term><term>Autoanticorps (pharmacologie)</term><term>Cellules endothéliales ()</term><term>Cellules épithéliales ()</term><term>Humains</term><term>Immunoglobuline A (sang)</term><term>Immunoglobuline G (sang)</term><term>Immunoglobuline M (sang)</term><term>Lignée cellulaire</term><term>Protéines nucléocapside (immunologie)</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Test ELISA</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin A</term><term>Immunoglobulin G</term><term>Immunoglobulin M</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Nucleocapsid Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Autoantibodies</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Endothelial Cells</term><term>Epithelial Cells</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Protéines nucléocapside</term><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Autoanticorps</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Immunoglobuline A</term><term>Immunoglobuline G</term><term>Immunoglobuline M</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Cell Line</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Cellules endothéliales</term><term>Cellules épithéliales</term><term>Humains</term><term>Lignée cellulaire</term><term>Test ELISA</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The severe acute respiratory syndrome (SARS) is caused by infection with the SARS-associated coronavirus (SARS-CoV) and characterized by severe pulmonary inflammation and fibrosis. In this study, the development of autoantibodies against human epithelial cells and endothelial cells in patients with SARS at different time periods (the first week: phase I, 1 month after the disease onset: phase II/phase III) were investigated. Antibodies in sera of patients and healthy controls against: (1) A549 human pulmonary epithelial cell-line, (2) human umbilical venous endothelial cells (HUVEC), (3) primary human pulmonary endothelial cells (HPEC) were detected by cell-based ELISA and indirect immunofluorescence staining. The results revealed that serum levels of IgG anti-A549 cells antibodies, IgG anti-HUVEC antibodies, and IgM anti-HPEC antibodies were significantly higher in SARS patients at phase II/phase III than those in healthy controls. Sera from SARS patients at phase II/phase III could mediate complement dependent cytotoxicity against some A549 cells and HPEC. It is concluded that some autoantibodies against human epithelial cells and endothelial cells would be developed after SARS-CoV infection and this phenomenon may indicate post-infectious cellular injury and also induce SARS-induced immunopathology.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16032747</PMID><DateCompleted><Year>2005</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0146-6615</ISSN><JournalIssue CitedMedium="Print"><Volume>77</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J. Med. Virol.</ISOAbbreviation></Journal><ArticleTitle>Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection.</ArticleTitle><Pagination><MedlinePgn>1-7</MedlinePgn></Pagination><Abstract><AbstractText>The severe acute respiratory syndrome (SARS) is caused by infection with the SARS-associated coronavirus (SARS-CoV) and characterized by severe pulmonary inflammation and fibrosis. In this study, the development of autoantibodies against human epithelial cells and endothelial cells in patients with SARS at different time periods (the first week: phase I, 1 month after the disease onset: phase II/phase III) were investigated. Antibodies in sera of patients and healthy controls against: (1) A549 human pulmonary epithelial cell-line, (2) human umbilical venous endothelial cells (HUVEC), (3) primary human pulmonary endothelial cells (HPEC) were detected by cell-based ELISA and indirect immunofluorescence staining. The results revealed that serum levels of IgG anti-A549 cells antibodies, IgG anti-HUVEC antibodies, and IgM anti-HPEC antibodies were significantly higher in SARS patients at phase II/phase III than those in healthy controls. Sera from SARS patients at phase II/phase III could mediate complement dependent cytotoxicity against some A549 cells and HPEC. It is concluded that some autoantibodies against human epithelial cells and endothelial cells would be developed after SARS-CoV infection and this phenomenon may indicate post-infectious cellular injury and also induce SARS-induced immunopathology.</AbstractText><CopyrightInformation>(c) 2005 Wiley-Liss, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yao-Hsu</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yu-Hui</ForeName><Initials>YH</Initials></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Ya-Hui</ForeName><Initials>YH</Initials></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Chung-Min</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li-Chieh</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yu-Tsan</ForeName><Initials>YT</Initials></Author><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Bor-Luen</ForeName><Initials>BL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019590">Nucleocapsid Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004847" MajorTopicYN="N">Epithelial Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019590" MajorTopicYN="N">Nucleocapsid Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>10</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16032747</ArticleId><ArticleId IdType="doi">10.1002/jmv.20407</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002631 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002631 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:16032747
|texte= Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:16032747" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |